Dynavax Technologies Corporation announced unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported total revenues of $2,085,000 against $2,350,000 a year ago. Loss from operations was $20,879,000 against $15,848,000 a year ago. Net loss was $20,825,000 or $0.11 basic and diluted per share against $16,505,000 or $0.11 basic and diluted per share a year ago.

Dynavax Technologies Corporation announced that the company's board of directors has appointed Eddie Gray as chief executive officer and a member of Dynavax's board, effective May 1, 2013. Mr. Gray will succeed Dino Dina, M.D., Chief Executive Officer. Dr. Dina will remain a consultant to the company for a transition period and plans to continue serving as a member of the Dynavax board. The company also indicated that Tyler Martin, M.D., President, is departing from Dynavax on May 31, 2013 and plans to remain a consultant for a transition period. Most recently, Mr. Gray served as the President of Pharmaceuticals Europe at GlaxoSmithKline plc since 2008 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr. Gray was with SmithKline Beecham from 1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the US, Vice President and Director of the Vaccines Business Unit in the US, and Vice President and General Manager of Pharmaceuticals in Canada.

Dynavax Technologies Corporation proposed to approve an amendment to the company's Sixth Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 250,000,000 to 350,000,000 shares.